Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x100px
Document › Details

ThromboGenics N.V.. (5/11/17). "Press Release: ThromboGenics Business Update – Q1 2017. Progressing Innovative Diabetic Eye Disease Clinical and Pre-Clinical Portfolio". Leuven.

Organisations Organisation ThromboGenics N.V. (Euronext Brussels: THR)
  Today Oxurion N.V. (Euronext Brussels: OXUR)
  Group Oxurion (Group)
  Organisation 2 Bicycle Therapeutics Ltd.
  Group Bicycle Therapeutics (Group)
Products Product THR-317 (ThromboGenics)
  Product 2 THR-409 (ThromboGenics)
Person Person De Haes, Patrik (ThromboGenics 200808– CEO before Roche Diagnostics)


> ThromboGenics continues to focus on progressing its portfolio of novel medicines for the treatment of diabetic eye disease

> ThromboGenics recruited the first patients in the Phase II clinical study evaluating THR-317 (anti-PlGF) for Diabetic Macular Edema (DME) in January 2017. The trial is assessing THR-317’s ability to improve best-corrected visual acuity (BCVA) and to reduce central retinal thickness in subjects with DME

> ThromboGenics is conducting a Phase IIa clinical study (CIRCLE) evaluating THR-409 (ocriplasmin) to induce a complete posterior vitreous detachment (total PVD) and prevent patients with non-proliferative diabetic retinopathy from progressing to proliferative diabetic retinopathy, a serious sight threatening condition. Following the CIRCLE study protocol amendment, allowing inclusion of patients with less severe non-proliferative diabetic retinopathy, recruitment has picked  up

> ThromboGenics is making good progress with its preclinical pipeline :

–– THR-687 is being developed to treat a broad range of patients with diabetic retinopathy, with or without DME. THR-687 is expected to enter the clinic around the end of 2017

–– THR-149 is being developed to treat edema associated with diabetic retinopathy. ThromboGenics achieved an important milestone in its alliance with Bicycle Therapeutics when THR-149 commenced formal toxicology studies. THR-149 is expected to enter the clinic in H1 2018

> New data presentations and posters (12 in total) delivered at ARVO (the Association for Research in Vision and Ophthalmology), a major ophthalmology conference held in Baltimore, US.  The majority of these showed additional positive real world data on ocriplasmin, but also a presentation on ThromboGenics anti-PlGF, THR-317.

> The European Commission confirmed orphan drug designation for TB-403 developed by ThromboGenics’ subsidiary, Oncurious for medulloblastoma, the most common pediatric malignant brain tumor, in January 2017

> Cash and investments were €73.3 million as of the end of March 2017, compared with €80.1 million at the end of December 2016

Leuven, Belgium – 11th May 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, today issues a business update for the three months period ending 31 March 2017.

ThromboGenics is focused on developing novel medicines for diabetic eye disease, particularly diabetic retinopathy (DR) and diabetic macular edema (DME).

Over the last three years, ThromboGenics has developed an attractive pipeline of disease modifying drug candidates. The pipeline consists of THR-409, THR-317, both from its in-house research, as well as THR-149 which resulted from a research collaboration with Bicycle Therapeutics, and THR-687, which was in-licensed from Galapagos NV.

These products all have different modes of action and allow the Company to address the four key segments of the evolving diabetic eye disease market:

> Non-proliferative DR
> Proliferative DR
> Non-proliferative DR with DME
> Proliferative DR with DME
ThromboGenics believes its diabetic eye disease pipeline is one of the strongest in the industry.

Dr. Patrik De Haes, ThromboGenics’ CEO,said: “We are making good progress with our exciting drug development pipeline of potential new disease modifying medicines for the treatment of diabetic eye disease. Diabetic Retinopathy and Diabetic Macular Edema (DME) are significant indications where there are clear unmet medical needs and a strong demand for improved or add-on treatment options. With our ambitious pipeline and current cash resources we believe we are well positioned to address all key segments of the diabetic eye disease market and to generate attractive returns for our shareholders.”

Click here to see the full press release [ ]

Record changed: 2023-06-05


Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Oxurion (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px

» top